Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9779MR)

This product GTTS-WQ9779MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9779MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2949MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ5286MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ6171MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ11957MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ8952MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ10373MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ5484MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ13261MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06252616
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW